Cesarean DeliveryPainPregnancyDrugPhase 4
What this study is
In this study the researchers are randomizing pregnant patients coming for elective cesarean delivery to receive either intrathecal buprenorphine or morphine for their analgesia.
What's being tested
- buprenorphine
Intervention · DRUG
60 mcg buprenorphine intrathecal
- morphine
Intervention · DRUG
125mcg morphine intrathecal
Study details
- Official title
- The BUMP Trial: Intrathecal Buprenorphine Versus Morphine for Postcesarean Analgesia-A Randomized Noninferiority Trial
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Conditions
- Cesarean Delivery
- Enrolling
- 180 people
- Starts
- 2026-10-07
- Est. completion
- 2028-08
- Design
- Quadruple-blind, randomized, parallel groups, Phase 4
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 19 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Presenting for singleton elective cesarean delivery at term gestation.
You can't join if
- Allergy to buprenorphine or morphine
- Will not have neuraxial anesthesia
- Chronic pain conditions
- Opiate based medications
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openMount Sinai Hospital
New York, New York, United States
- Daniel Katz, MD · Contact212-241-7475daniel.katz@mountsinai.org
- Daniel Katz · Principal investigator
Recruiting
Study team
Sponsor
Icahn School of Medicine at Mount Sinai
Study ID STUDY-26-00705
Principal investigator
Daniel Katz
Icahn School of Medicine at Mount Sinai
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.